A Randomised PhIII study to assess the effect of 100 mg SC Mepolizumab in the nasal polyp score and symptoms in subjects with bilateral Nasal polyps (NP) and in current need of NP surgery

Next Previous
Trial Profile

A Randomised PhIII study to assess the effect of 100 mg SC Mepolizumab in the nasal polyp score and symptoms in subjects with bilateral Nasal polyps (NP) and in current need of NP surgery

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Nasal polyps
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 26 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top